Therapeutic interchange; Bd. of Pharmacy to convene work group to review authority of pharmacists.
Summary
SB745 directs the Virginia Board of Pharmacy to convene a stakeholder work group to study pharmacists’ current authority to initiate therapeutic interchange. The work group must review how therapeutic interchange operates across health carriers, health plans, and other reimbursement arrangements, including plans governed by ERISA, and then recommend ways to streamline and modernize the process.
The bill specifically asks the work group to consider therapeutic interchange in the context of prescription drug shortages, where faster substitution of therapeutically equivalent medications may be especially important. The group is required to include representatives from state health and licensing boards, pharmacy and medical organizations, hospitals, health plans, drugstore chains, pediatric and patient advocacy groups, and to report its findings and recommendations to the Governor and legislative health committee chairs by November 15, 2025.
Impact
The bill does not directly change pharmacists’ authority or amend substantive pharmacy practice statutes immediately; instead, it creates a formal study and recommendation process through the Board of Pharmacy. Its practical effect is to gather stakeholder input on current law and identify potential regulatory or statutory changes related to therapeutic interchange, including issues involving insurance coverage and ERISA-covered plans. The bill may influence future legislation or administrative action affecting pharmacists, prescribers, insurers, and patients.
Sentiment
The voting history suggests broad overall support for the bill, with the Senate passing it unanimously and the House ultimately approving it by a narrow margin. Committee and subcommittee votes also favored reporting the measure, though not without some opposition in the House process. The general tone appears to be one of interest in improving pharmacy practice and drug-shortage response, tempered by caution from some members about the scope or implications of changing therapeutic interchange authority.
Contention
The main points of contention appear to center on how far pharmacists’ authority should extend to initiate therapeutic interchange and whether changes could affect physician oversight, insurer practices, or existing reimbursement rules. Because the bill includes ERISA-covered plans and multiple health-system stakeholders, it likely raised concerns about federal-state interaction, implementation complexity, and the balance between efficiency and clinical control. Opposition in the House committee and floor vote indicates that some lawmakers were not fully comfortable with the proposal, even though the measure only establishes a work group rather than changing the law directly.